Login to Your Account

Adolor's Entereg Hits In Second Phase III; Stock Jumps 29 Percent

By Kim Coghill

Wednesday, September 24, 2003
A team of executives from Adolor Corp. and partner GlaxoSmithKline plc Tuesday said statistically significant data from a second Phase III study of Entereg in the management of postoperative ileus nudges the companies one step closer to submitting a regulatory package next year. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription